Doxorubicin-isoniazid conjugate regulates immune response and tumor microenvironment to enhance cancer therapy.
Int J Pharm
; 631: 122509, 2023 Jan 25.
Article
in En
| MEDLINE
| ID: mdl-36549403
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Isoniazid
Limits:
Female
/
Humans
Language:
En
Journal:
Int J Pharm
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: